Publications from the Cincinnati Center for Eosinophilic Disorders
Zhang S, Cavallaro D, Xia M, Morgenstern NBB, Shoda T, Osswald GA, Bolton S, Mukkada V, Derakhshan TM, Dunn J, Felton J, Rochman M, Caldwell JM, Rothenberg ME. Effects of C3aR-activated mast cells in eosinophilic esophagitis. United States. 2025. PubMed PMID: 40502038.
Osonoi K, Sawada A, Maekawa Y, Yamaguchi M, Yamada S, Matsuyama K, Rochman M, Rothenberg ME, Han X, Matsuda N, Suzuki I, Tanaka F, Fujiwara Y, Shoda T. Involvement of IL-13–induced dysregulation of the BDNF–NTRK2 pathway in symptoms of eosinophilic esophagitis. Allergy. 2025. Epub 2025 May 13. doi:10.1111/all.16592. PubMed PMID: 40358555.
Chang JW, Dellon ES, Mukkada V. Budesonide oral suspension: Expanding the toolkit for eosinophilic esophagitis. Am J Gastroenterol. 2025;120(1):16–19. Epub 2024 Sep 23. doi:10.14309/ajg.0000000000003090. PubMed PMID: 39311427; PMCID: PMC11695148.
Dellon ES, Katzka DA, Mukkada VA, Collins MH, Falk GW, Richmond CA, Terreri B, Thakur M, Boules M, Goodwin B, Hirano I. Long-term safety and efficacy of budesonide oral suspension for eosinophilic esophagitis: A 4-year, phase 3, open-label study. Clin Gastroenterol Hepatol. 2025. Epub 2025 Feb 13. doi:10.1016/j.cgh.2024.12.024. PubMed PMID: 39954913.
Parrish KM, First N, Kamanova J, Williams TL, Johnson S, King J, Scanlon KM, Azouz NP, Mattoo S, Skerry C, Gestal MC. The Bordetella type III secretion system effector BteA targets host eosinophil–epithelial signaling to promote IL-1Ra expression and persistence. Commun Biol. 2025;8(1):1484. doi:10.1038/s42003-025-08884-1. PubMed PMID: 41116045.
Brown AP, Parameswaran S, Cai L, Elston S, Pham C, Barski A, Weirauch MT, Ji H. Silencing TET1 expression alters the epigenomic landscape and amplifies transcriptomic responses to allergen in airway epithelial cells. Environ Epigenet. 2025;11(1):dvaf007. doi:10.1093/eep/dvaf007. PubMed PMID: 40401166.
Hwee J, Huynh L, da Costa W, Rothenberg ME, Duh MS, Alfonso-Cristancho R. Steroid-sparing benefits of biologic use in hypereosinophilic syndrome and substantial disease burden across subtypes. Front Allergy. 2025;6:1605397. doi:10.3389/falgy.2025.1605397. PubMed PMID: 40486501.
Wilburn AN, Korkmaz RÜ, McAlees JW, Hargis JM, Shirdel S, Lingel I, Watanabe-Chailland M, Romick-Rosendale L, Schmudde I, Bridges JP, Chougnet CA, Deshmukh H, Zacharias WJ, Köhl J, Konig P, Laumonnier Y, Rothenberg ME, Haslam DB, Lewkowich IP. Maternal antibiotic exposure–mediated alterations in basal and allergen-induced lung function are associated with altered recruitment of eosinophils to the developing lung. Front Immunol. 2025;16:1715675. doi:10.3389/fimmu.2025.1715675. PubMed PMID: 41488660.
Collins MH, Pan Z, Yang GY, Arva NC, Pletneva MA, Martin LJ, Aceves S, Chehade M, Dellon ES, Spergel JM, Menard-Katcher P, Peterson KA, Khoury P, Gonsalves N, Gupta SK, Davis CM, Falk GW, Wechsler JB, Pesek R, Hiremath G, Leung J, Katzka DA, Furuta GT, Rothenberg ME. Patient-reported outcome scores are comparable in multiregional versus uniregional eosinophilic esophagitis. Gastro Hep Adv. 2025;4(9):100753. doi:10.1016/j.gastha.2025.100753. PubMed PMID: 41399343.
Collins MH, Rothenberg ME, Dellon ES, Bredenoord AJ, Hirano I, Leung J, Sun X, Glotfelty L, Shabbir A. Dupilumab improves histopathologic features in patients with eosinophilic esophagitis: LIBERTY EoE TREET study results. Gastro Hep Adv. 2025;4(6):100646. doi:10.1016/j.gastha.2025.100646. PubMed PMID: 40487268.
Kliewer KL, Abonia JP, Aceves SS, Atkins D, Bonis PA, Capocelli KE, Chehade M, Collins MH, Dellon ES, Fei L, Furuta GT, Gupta SK, Kagalwalla A, Leung J, Mir S, Mukkada VA, Pesek R, Rosenberg C, Shoda T, Spergel JM, Sun Q, Wechsler JB, Yang GY, Rothenberg ME. One-food versus 4-food elimination diet for pediatric eosinophilic esophagitis: A multisite randomized trial. J Allergy Clin Immunol. 2025;155(2):520–532. doi:10.1016/j.jaci.2024.08.023. PubMed PMID: 39233016.
Lawson LP, Parameswaran S, Panganiban RA, Constantine GM, Weirauch MT, Kottyan LC. Update on the genetics of allergic diseases. J Allergy Clin Immunol. 2025;155(6):1738–1752. doi:10.1016/j.jaci.2025.03.012. PubMed PMID: 40139464.
McGowan EC, Wright BL, Ruffner MA, Pesek RD, Rothenberg ME, Spergel JM, Dellon ES, Aceves SS. Eosinophilic esophagitis (EoE): Allergy & immunology perspective on the updated guidelines. J Allergy Clin Immunol. 2025. doi:10.1016/j.jaci.2025.04.026. PubMed PMID: 40339609.
Melo RCN, Rothenberg ME. Imaging eosinophil secretory granules: From storage containers to active, immune responder organelles. J Allergy Clin Immunol. 2025;155(2):414–417. doi:10.1016/j.jaci.2024.12.1069. PubMed PMID: 39709031.
Rochman M, Rothenberg ME. Immune functions of the esophagus. J Allergy Clin Immunol. 2025. doi:10.1016/j.jaci.2025.12.001. PubMed PMID: 41386478.
Mehta P, Pan Z, Furuta GT, Kliewer K, Consortium of Eosinophilic Gastrointestinal Disease R. Empiric elimination diets for eosinophilic esophagitis: Barriers, facilitators, and impact on quality of life. J Allergy Clin Immunol Pract. 2025;13(2):434–436. doi:10.1016/j.jaip.2024.10.030. PubMed PMID: 39489217.
Rochman Y, Kotliar M, Klingler AM, Rochman M, Alameh MG, Melamed JR, Osswald GA, Caldwell JM, Felton JM, Mack LE, Hargis J, Lewkowich IP, Barski A, Weissman D, Rothenberg ME. Allergen-specific mRNA–lipid nanoparticle therapy for prevention and treatment of experimental allergy in mice. J Clin Invest. 2025;135(21). doi:10.1172/JCI194080.
Hīwee J, Huynh L, Pongdee T, Rothenberg ME, Alfonso-Cristancho R, da Costa Junior W, Duh MS. High disease burden and oral corticosteroid use in patients with hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis. J Clin Med. 2025;14(12). doi:10.3390/jcm14124309.
Ho CN, Fjällbrant H, Dellon ES, Santander C, Rothenberg ME, Bailey J, McFadden S, Ritchie J. Patient experience with eosinophilic esophagitis symptoms and impacts on daily life based on in-trial qualitative interviews. J Patient Rep Outcomes. 2025;9(1):3. doi:10.1186/s41687-025-00836-x. PubMed PMID: 39777591.
Bansal P, Dellon E, Katzka D, Falk G, Mukkada V, Terreri B, Schaeffer-Koziol C, Blau J, Gugiu C, Goodwin B, Tahir M. Effect of randomized treatment withdrawal of budesonide oral suspension on durability of dysphagia symptom improvement in eosinophilic esophagitis. J Allergy Clin Immunol. 2025;155(2):ab130. doi:10.1016/j.jaci.2024.12.413.
Dellon ES, Collins MH, Bredenoord AJ, Philpott H, Biedermann L, Dulcine M, Nguyen-Cleary T, Su C, Yu J, Tan H, Cataldi F, Wu J, Wang W, Clax P, Woolcott JC, Hirano I. Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): A double-blind, placebo-controlled, randomized phase 2 trial. Lancet Gastroenterol Hepatol. 2025. doi:10.1016/S2468-1253(25)00062-7. PubMed PMID: 40381637.
Felton JM, Edsall LE, Troutman TD, Mack L, Kotliar M, Morgenstern NBB, Psaila AM, Rochman M, Klingler AM, Osswald GA, Zhang S, Dunn JLM, Wronowski B, Shoda T, Caldwell JM, Herro R, Barski A, Quinlan KGR, Weirauch MT, Rothenberg ME. Epigenetic and transcriptional programming of murine eosinophils in the esophagus. Nat Commun. 2025;16(1):10454. doi:10.1038/s41467-025-65440-5.
Rochman M, Kellerman K, Jankowski MP, Rothenberg ME. The oesophagus as an immune organ. Nat Rev Gastroenterol Hepatol. 2025. doi:10.1038/s41575-025-01086-4.
Chehade M, Dellon ES, Pesek RD, Collins MH, Ashok D, Hörning A, Liu R, Louisias M, Radin A. Long-term treatment with dupilumab maintains histologic and endoscopic improvement in children with eosinophilic esophagitis: Open-label extension of the EoE KIDS study. Z Gastroenterol. 2025;63(8):e404–e405. doi:10.1055/s-0045-1810698. Thieme E-Journals - Zeitschrift für Gastroenterologie / Abstract
Collins MH, Gonsalves N, Ashok D, Turner KO, Schilling D, Xia C, Zaghloul S, Raphael BP, Angello JT, Radwan A. Dupilumab normalizes key histopathologic features of eosinophilic esophagitis in adults and adolescents: Post hoc analysis of the phase III LIBERTY EoE TREET study. Z Gastroenterol. 2025;63(8):e403–e404. doi:10.1055/s-0045-1810697. Thieme E-Journals - Zeitschrift für Gastroenterologie / Abstract
